MFN Pricing Just Made Your China NRDL Strategy a U.S. Liability – And Where Advisory Firms Struggle
- 5 days ago
- 4 min read
The pricing concession your team agrees in a Beijing NRDL negotiation can now move your U.S. valuation model. Most advisors will tell you that. Very few can actually help you model it, defend against it, and close deals that account for it. Here is what the problem looks like, and what working with an advisor who operates in this specific lane actually delivers.
The Policy Shift That Changed the Calculus
On May 12, 2025, President Trump signed an executive order directing HHS to establish a Most-Favored-Nation price target defined as the lowest price in any OECD country with a GDP per capita of at least 60% of the U.S. (White House). The 2025 MFN model applies to all new drug launches across Commercial, Medicare, and Medicaid channels.
The mechanism matters more than the headline. In December 2025, CMS published two proposed models, GLOBE for Part B drugs and GUARD for Part D, that would incorporate international price benchmarks into Medicare drug rebate calculation methodologies on a mandatory basis (CMS). These are proposed rules, not yet enacted. Legal uncertainty remains real. But the direction of travel is locked in, and manufacturer behavior has already shifted: nine manufacturers including Amgen, Bristol Myers Squibb, Gilead, Merck, Novartis, and Sanofi have already signed voluntary agreements to make MFN prices available to Medicaid programs.
China is not named explicitly in the MFN framework. It does not need to be. A negotiated NRDL price that sits below the comparable OECD basket anchors the reference point. That is the exposure, and it is live now.
Why the China BD Market Makes This Urgent
The volume and velocity of China-to-global pharma deals has made this a board-level issue, not a regulatory footnote. The number of total cross-border licensing deals of Chinese biotech products increased 120% from 42 in 2022 to 93 in 2025, while total upfront value of those arrangements increased roughly 400%, from $1.1 billion in 2022 to $5.6 billion last year, according to Evaluate. Concord The average upfront value for a licensing deal or acquisition increased from $52 million to $172 million between 2022 and early 2026 (Fierce Biotech)
This is no longer a niche activity. In H1 2025 alone, China deals accounted for 44.5% of the global licensing total (Premia). European companies like AstraZeneca, GSK, and others signed agreements with Chinese companies in H1 2025 alone, including AstraZeneca's R&D collaboration with CSPC Pharmaceutical valued at over $5 billion and GSK's agreement with Jiangsu Hengrui covering around a dozen oncology programmes worth up to $12 billion (BioPharma APAC) The assets being licensed, ADCs, bispecifics, GLP-1 candidates, cell therapies, are exactly the product classes where NRDL pricing is most aggressive and where MFN sensitivity is highest.
In 2024, among 249 unlisted candidates, 89 were successfully listed on the NRDL with an average price reduction of 63%, listed within a median time of 1.1 years after approval. The negotiation success rate for innovative drugs first launched globally in China was over 90%. A 60% reduction in the Chinese reimbursed price for a drug where China represents 20% of global forecast revenue, propagated through even a modest 5 to 10% downward movement in U.S. pricing expectations, reduces global peak sales estimates by 10 to 15% depending on product weighting. For a deal being priced at transaction, that gap is material. (Ispor)
What B2B Execution in This Lane Actually Looks Like
For a European pharma company actively considering or managing China-originated assets, the advisory mandate is not a research report. It is a sequence of decisions that need to be made with precision and speed, each carrying commercial and valuation consequences.
Asset identification and shortlisting.
The China biotech market is producing volume at a pace that is structurally difficult for European BD teams to monitor. Since 2022, China biotechs have developed 639 first-in-class drug candidates, a 360% increase from 137 candidates between 2018 and 2021. Not all of them are EMA-ready, EU JCA-compatible, or commercially viable in European indication sequencing. (Fierce Biotech) Narrowing that universe to a shortlist that reflects your therapeutic focus, regulatory pathway, and commercial criteria is the first deliverable, and it requires genuine NMPA-to-EMA translation capability, not macro analysis.
NRDL scenario modeling integrated with deal valuation.
For any asset with existing or anticipated NRDL exposure, three scenarios need to be modeled before deal terms are agreed: no listing, moderate discount, and steep discount. Each scenario must be propagated through ex-China reference pricing assumptions and U.S. MFN sensitivity to produce a realistic valuation range. A single-scenario peak sales projection for an asset with China exposure is a liability in any serious negotiation. The counterparty will have done the analysis; you need to have done it too.
EU regulatory pathway assessment as a commercial input.
Whether a Chinese asset can be developed efficiently toward EMA approval, and under what timeline and evidence requirements, directly determines deal economics. EU JCA implications for HTA across multiple European markets also affect revenue forecasting in ways that require regulatory depth, not just market access familiarity. This due diligence layer is what separates a deal that closes cleanly from one that reprices six months later when the regulatory complexity becomes visible.
Deal mechanics that distribute cross-market pricing risk.
For assets with meaningful China pricing exposure, standard deal structures carry unquantified downside. Milestone structures tied to reimbursement outcomes, revenue-share adjustments linked to realized pricing, and earn-outs based on peak sales performance are the mechanisms that distribute that risk appropriately between parties. Drafting those terms requires someone who understands both the China pricing environment and the European deal context simultaneously.
The Bottom Line
Average upfront deal value for China biotech licensing has increased 230% from $52 million in 2022 to $172 million in early 2026. The assets are no longer cheap, the market is no longer opaque, and the pricing dynamics now cross borders in ways that affect U.S. valuation models and European HTA outcomes simultaneously.
European pharma companies that are evaluating Chinese assets, managing NRDL exposure, or structuring deals with China-side counterparties need an advisor who operates specifically in the China-to-Europe lane, with pharma BD execution capability, NMPA and EMA regulatory depth, and the capacity to translate pricing dynamics into investor-ready deal language. That is not a general advisory capability. It is a specific one.
SILREAL delivers a rapid NRDL-to-Global Valuation scenario pack: three scenarios, propagated U.S. sensitivity, and a one-page negotiation playbook designed to inform board decisions and transaction planning before they become reactive.
